Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Asenapine pharmacokinetics and tolerability in a pediatric population.

Dogterom P, Riesenberg R, de Greef R, Dennie J, Johnson M, Pilla Reddy V, Miltenburg AM, Findling RL, Jakate A, Carrothers TJ, Troyer MD.

Drug Des Devel Ther. 2018 Aug 30;12:2677-2693. doi: 10.2147/DDDT.S171475. eCollection 2018.

2.

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations.

Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M.

Clin Pharmacol Ther. 2018 May 1. doi: 10.1002/cpt.1103. [Epub ahead of print]

PMID:
29717476
3.

Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.

Pilla Reddy V, Walker M, Sharma P, Ballard P, Vishwanathan K.

CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):321-330. doi: 10.1002/psp4.12289. Epub 2018 Mar 15.

4.

Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 May;33(5):1305-6. doi: 10.1007/s11095-016-1888-2. Epub 2016 Mar 10. No abstract available.

5.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 Apr;33(4):1003-17. doi: 10.1007/s11095-015-1846-4. Epub 2015 Dec 30. Erratum in: Pharm Res. 2016 May;33(5):1305-6.

PMID:
26718955
6.

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2014 Oct;31(10):2605-17. doi: 10.1007/s11095-014-1358-7. Epub 2014 May 3.

PMID:
24792824
7.

Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.

Pilla Reddy V, Kozielska M, Johnson M, Mafirakureva N, Vermeulen A, Liu J, de Greef R, Rujescu D, Groothuis GM, Danhof M, Proost JH.

J Clin Psychopharmacol. 2013 Dec;33(6):731-9. doi: 10.1097/JCP.0b013e3182a4ee2c.

PMID:
24113674
8.

Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.

Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH.

Schizophr Res. 2013 May;146(1-3):153-61. doi: 10.1016/j.schres.2013.02.010. Epub 2013 Mar 6.

9.

Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.

Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH.

Schizophr Res. 2013 May;146(1-3):144-52. doi: 10.1016/j.schres.2013.02.011. Epub 2013 Mar 6.

10.

Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.

Kozielska M, Pilla Reddy V, Johnson M, de Ridder F, Vermeulen A, Liu J, Groothuis GM, Danhof M, Proost JH.

Schizophr Res. 2013 May;146(1-3):53-8. doi: 10.1016/j.schres.2013.01.022. Epub 2013 Feb 20.

PMID:
23434198
11.

Modelling and simulation of placebo effect: application to drug development in schizophrenia.

Pilla Reddy V, Kozielska M, de Greef R, Vermeulen A, Proost JH.

J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):377-88. doi: 10.1007/s10928-012-9296-7. Epub 2013 Jan 12. Review.

PMID:
23315146
12.

Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2012 Jul;29(7):1932-48. doi: 10.1007/s11095-012-0722-8. Epub 2012 Mar 22.

13.

Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Pilla Reddy V, Kozielska M, Johnson M, Suleiman AA, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH.

Clin Pharmacokinet. 2012 Apr 1;51(4):261-75. doi: 10.2165/11598460-000000000-00000.

PMID:
22420580
14.

Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements.

Pilla Reddy V, Petersson KJ, Suleiman AA, Vermeulen A, Proost JH, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1:e1. doi: 10.1038/psp.2012.9.

15.

Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.

Jayaraman R, Pilla Reddy V, Pasha MK, Wang H, Sangthongpitag K, Yeo P, Hu CY, Wu X, Xin L, Goh E, New LS, Ethirajulu K.

Drug Metab Dispos. 2011 Dec;39(12):2219-32. doi: 10.1124/dmd.111.041558. Epub 2011 Aug 26.

16.

Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH.

Clin Pharmacokinet. 2011 Jul;50(7):429-50. doi: 10.2165/11590590-000000000-00000.

PMID:
21651312
17.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2011 Oct;28(10):2490-504. doi: 10.1007/s11095-011-0477-7. Epub 2011 Jun 7.

Supplemental Content

Loading ...
Support Center